JAK1 and non-small cell lung carcinoma: In addition, the phosphorylation level of JAK1 was significantly increased in patients with NSCLC and its high expression was associated with poor prognosis, suggesting that phosphorylated JAK1 could be used as a predictor of NSCLC treatment (43).